Biotechnology stocks have delivered strong gains in 2026, supported by encouraging clinical trial results, regulatory approvals, and growth in drug sales. Investors’ appetite for high-growth companies has also edged higher, as depicted by the S&P 500 biotechnology sector gaining 31% year-to-date, in line with the Insider Monkey...
